OncoSec Medical Inc. (ONCS), a company developing itsadvanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulsetherapy to treat solid tumor cancers, published a blog post entitled“Introduction: Why social-digital now?”on Mr. Dhillon’s blog site (punitdhillon.com)which was republished on TheChairmansBlog.com.
OncoSec’sPresident and CEO, Punit Dhillon, blogs about how social media haschanged the landscape of communication between patients, doctors andcompanies developing therapies for life-threatening conditions. Hehighlights the importance of adapting to this change by writing,“…to be successful, we are aware that we must be novel in ourapproach and to take advantage of tools that might not otherwise betraditionally used by companies in our space.” Mr. Dhillon outlineswhat readers can expect from his blog and encourages feedback viasocial media.
OncoSec MedicalInc. is a biopharmaceutical company developing itsadvanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulsetherapy to treat solid tumor cancers. ImmunoPulse and NeoPulsetherapies address an unmet medical need and represent apotential solution, for less invasive and less expensive therapiesthat are able to minimize detrimental effects resulting fromcurrently available cancer treatments such as surgery, systemicchemotherapy or immunotherapy and other treatment alternatives. OncoSec Medical's core technology is based upon itsproprietary use of an electroporation platformto dramatically enhance the delivery and uptake of alocally delivered DNA-based immunocytokine (ImmunoPulse) orchemotherapeutic agent (NeoPulse). Treatment of varioussolid cancers using these powerful and targeted anti-canceragents has demonstrated selective destruction of cancerouscells while sparing healthy normal tissues during early and latestage clinical trials. OncoSec's clinical programs include threePhase II clinical trials for ImmunoPulse targeting lethal skincancers. More information is available at http://www.oncosec.com/.
- Biotechnology Science